Sun Pharma will increase its field staff in India by 10% this fiscal year

Pharmaceutical major Sun Pharma plans to increase its domestic workforce by 10% in the current fiscal year to pursue the twin goals of brand focus and geographic expansion, according to a senior company official . The Mumbai-based big pharma company, which is the world’s fourth largest specialty generic drug maker, currently employs around 11,000 medical representatives (MRs) and related staff in the country.

“The field force expansion completed in FY21 has been very successful and given current market conditions, we will be undertaking a further expansion of approximately 10% of our field force in FY21. 23, driven by the twin goals of brand focus and geographic expansion,” Sun Pharmaceutical Industries (India Business) CEO Kirti Ganorkar said on a call with analysts.

The company’s formulations sales in India for the year FY22 amounted to Rs 12,759 Crore, registering a strong growth of 23% from FY 2020-21.

Read also :

For the fourth quarter ended March 31, 2022, formulations revenue in India was Rs 3,096 crore, approximately 16% higher than the January to March quarter of FY21. In response to a question , Ganorkar called the planned increase in field strength “more like organic growth.”

“We are expanding into geographies where we had little or no presence. So it’s nothing to say that we look at the competition and then expand. So wherever we see growth opportunities in the territories where we are expanding,” he said. Noted. Additionally, the company has a large product portfolio that it needs to “declutter,” Ganorkar said.

“That’s why we are increasing in terms of the number of RMs as well as in terms of the number of business units, which promote the products to doctors. So that’s more our growth strategy going forward,” did he declare. Ganorkar said the company has seen growth in most therapies where it has a presence.

“Growth was driven by a combination of factors such as normalized market conditions and improved patient flow to medical clinics, which resulted in higher growth in the chronic and semi-chronic segments. New products also contributed to the growth and we are seeing good momentum in products launched over the past 24 months,” he noted. In the fourth quarter, the company introduced 11 new products to the Indian market.

Supported by more than 40 manufacturing plants, Sun Pharma serves more than 100 countries around the world. In FY22, the company’s revenue topped the $5 billion mark while adjusted net income topped the $1 billion mark.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button